Skip to content
OpenCapital
Get started

Tarsus Pharmaceuticals, Inc. TARS Accretion (Amortization) of Discounts and Premiums, Investments

Accretion (Amortization) of Discounts and Premiums, Investments at other companies

Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
-$394K+90.4%

Other financials

Income statement

See full
Revenue$162.1M+107%
Gross profit$152.7M+109%
Operating income-$6.1M+76.7%
Net income-$7.0M+72.3%
EPS (diluted)-$0.16+75.0%

Balance sheet

See full
Cash & equivalents$104.2M-41.6%
Total debt$88.7M+22.5%
Total equity$349.0M+1.9%
Total assets$581.1M+16.1%

Cash flow

See full
Operating cash flow-$24.7M-19.4%
CapEx$5.8M+886%
Free cash flow-$30.5M-43.4%

Valuation

See full
Market cap$2.85B+41.1%
Enterprise value$2.83B+47.8%
P/S5.3×-3.3×

Profitability

See full
Gross margin42.7%—
Operating margin-9.5%-4.2pp
Net margin-9%-4.0pp
FCF margin-28%-12.6pp

Returns & leverage

See full
Return on equity-14%-5.2pp
Debt / equity0.3×0.0×
Current ratio3.7×-1.8×

Where this comes from

Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.

The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tarsus Pharmaceuticals, Inc.'s accretion (amortization) of discounts and premiums, investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tarsus Pharmaceuticals, Inc.'s accretion (amortization) of discounts and premiums, investments?
Tarsus Pharmaceuticals, Inc. (TARS) reported accretion (amortization) of discounts and premiums, investments of $849K in Q1 2026.
How has Tarsus Pharmaceuticals, Inc.'s accretion (amortization) of discounts and premiums, investments changed year-over-year?
Tarsus Pharmaceuticals, Inc.'s accretion (amortization) of discounts and premiums, investments decreased by 35.4% year-over-year, from $1.31M to $849K.
What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s accretion (amortization) of discounts and premiums, investments?
Over 3 years (2022 to 2025), Tarsus Pharmaceuticals, Inc.'s accretion (amortization) of discounts and premiums, investments has grown at a 60.9% compound annual growth rate (CAGR), from $1.32M to $5.48M.
What does accretion (amortization) of discounts and premiums, investments mean?
This reflects the non-cash adjustment to the carrying value of investment securities to account for the difference between the purchase price and the face value. It aligns the interest income recognized on the income statement with the effective interest method over the life of the investment. This metric is essential for understanding the non-cash components of operating cash flow derived from treasury management.